Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.
By M. F. Holick, N. Binkley, H.A. Bischoff-Ferrari, Catherine M. Gordon, D. A. Hanley, Robert P. Heaney, M. H. Murad, Connie M. Weaver. Journal of Clinical Endocrinology and Metabolism, 2011
10,197 citations recorded by the source corpus.
OBJECTIVE The objective was to provide guidelines to clinicians for the evaluation, treatment, and prevention of vitamin D deficiency with an emphasis on the care of patients who are at risk for deficiency. PARTICIPANTS The Task Force was composed of a Chair, six additional experts, and a methodologist. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS Consensus was guided by systematic reviews of evidence and discussions during several conference calls and e-mail communications. The draft prepared by the Task Force was reviewed successively by The Endocrine Society's Clinical Guidelines Subcommittee, Clinical Affairs Core Committee, and cosponsoring associations, and it was posted on The Endocrine Society web site for member review. At each stage of review, the Task Force received written comments and incorporated needed changes. CONCLUSIONS Considering that vitamin D deficiency is very common in all age groups and that few foods contain vitamin D, the Task Force recommended supplementation at suggested daily intake and tolerable upper limit levels, depending on age and clinical circumstances. The Task Force also suggested the measurement of serum 25-hydroxyvitamin D level by a reliable assay as the initial diagnostic test in patients at risk for deficiency. Treatment with either vitamin D(2) or vitamin D(3) was recommended for deficient patients. At the present time, there is not sufficient evidence to recommend screening individuals who are not at risk for deficiency or to prescribe vitamin D to attain the noncalcemic benefit for cardiovascular protection.
Subfields: Emergency Medicine, Genetics, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/7d9c91a8f6fed91cb371dda5c1ce0089981bc8e2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Emergency Medicine
In Genetics
In Pathology and Forensic Medicine
Citations in the corpus
- Vitamin D and Immune Function (2013, background): “While the tolerable upper daily limit given by the Endocrine Society is 10,000 IU [27], the more conservative Institute of Medicine (USA) considers a supplementation of up to 4000 IU/day to be safe [25,26].”
- Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness (2011, background): “The Endocrine Society’s recommendation of a daily vitamin D intake of 1500 to 2000 IU and target 25(OH)D level of greater than 30 ng/mL (75 nmol/L)((99)) is more sound advice yet is still conservative compared with our study results.”
- The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. (2012, background): “Nuclear hormone receptors including the VDR are further regulated by protein complexes that can be activators or repressors (15, 16).”
- Vitamin D deficiency 2.0: an update on the current status worldwide (2020, methodology): “A range of below 75 nmol/L (or 30 ng/ml) of serum/plasma 25(OH)D concentration is considered vitamin D deficiency by most authors [11, 12] .”
- Role of ROS and Nutritional Antioxidants in Human Diseases (2018, neutral): “Vitamin D Fatty ocean fish, sunlight (Holick et al., 2011).”
- EASL Clinical Practice Guidelines on nutrition in chronic liver disease (2018, neutral): “The prevalence of vitamin D deficiency in the general population ranges from 20 to 100% when referring to serum 25hydroxyvitamin D (25(OH)D) concentrations <20 ng/ml, and affects all age groups.(128) In patients with chronic liver disease vitamin D (25(OH)D) levels below 20 ng/ml have been reported ”